AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

634.950

-11.153-1.73%

Number of Gainers:6

Number of Losers:15

Number of Flat:22

PE:- -

High:645.436

Open:638.323

Low:632.715

Close:646.103

Volume:82.34M

Turnover:107.75M

Market Cap:90.27B

Float Cap:87.07B

Loading ...

Cynata Therapeutics - Fy2026 Loss from Ordinary Activities After Tax A$9.1 Mln

THOMSON REUTERS

Anteotech Ltd - FY Revenues from Ordinary Activities A$467,589

THOMSON REUTERS

Anteotech Ltd - Loss for Year Attributable A$4.9 Mln

THOMSON REUTERS

Immutep - FY Loss Attributable A$79.3 Mln

THOMSON REUTERS

Spotlight for Clinuvel Turning to Vitiligo Trial Readout

Monash IVF Group - Appoints Catherine West as Chair-Elect to Succeed Richard Davis as Chair

THOMSON REUTERS

Monash IVF Group Ltd-Mvf Board Succession and Renewal

THOMSON REUTERS

Monash IVF Group - Richard Henshaw to Retire on 28 October 2026; Neil Broekhuizen to Retire on 31 August 2026

THOMSON REUTERS

Monash IVF Group Ltd - Expects Financial Performance to Strengthen Through Year

THOMSON REUTERS

Monash IVF Group FY Revenue AUD 269.5 Million

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership In August 2026

Simply Wall St.

ASX August 2026 Stocks Estimated Below Fair Value

Simply Wall St.

CSL’s latest result suggests the worst may be over

Morning Star AU

NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus

Simply Wall St.

3 Founder Led Australian Stocks Built For Higher Rates

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?

Simply Wall St.

3 Penny Stocks With Real Revenue And Solid Balance Sheets

Simply Wall St.

Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report

Simply Wall St.

Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen

Simply Wall St.

Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/BK7508/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":634.9499,"timestamp":1789106399475,"preClose":646.1032,"halted":0,"volume":82340846,"delay":0,"changeRate":-0.017262,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-11.15332,"latestTime":"09-11 16:00:00 AEST","open":638.3234,"high":645.43604,"low":632.7152,"amount":107748358.18,"amplitude":0.019689,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789084800000,1789106400000]],"turnoverRate":0.00323,"increases":7,"decrements":16,"flats":20,"marketCap":90265011743.75,"floatMarketCap":87070963229.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":645.43604,"amplitude":0.019689,"preClose":646.1032,"low":632.7152,"latestPrice":634.9499,"volume":82340846,"delay":0,"open":638.3234,"prevYearClose":644.3692,"prevWeekClose":666.366,"prevMonthClose":656.138,"prevQuarterClose":464.145,"fiveDayClose":666.366,"twentyDayClose":541.582,"sixtyDayClose":464.274,"secType":"PLATE","market":"AU","turnoverRate":0.00323,"marketCap":90265011743.75,"floatMarketCap":87070963229.625,"timestamp":1789106399475,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":6,"down":15,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663028432","title":"Cynata Therapeutics - Fy2026 Loss from Ordinary Activities After Tax A$9.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663028432?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:10","pubTimestamp":1788135014,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CYP.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663407270","title":"Anteotech Ltd - FY Revenues from Ordinary Activities A$467,589","url":"https://stock-news.laohu8.com/highlight/detail?id=2663407270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663407270?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:31","pubTimestamp":1788132711,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nFWN44P210:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7048","BK7501","ADO.AU","BK7036"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040720","title":"Anteotech Ltd - Loss for Year Attributable A$4.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040720?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:31","pubTimestamp":1788132711,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nFWN44P210:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7036","BK7508","BK7048","ADO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040149","title":"Immutep - FY Loss Attributable A$79.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040149?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:14","pubTimestamp":1788131660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nPLXZ3JZPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040960","title":"Spotlight for Clinuvel Turning to Vitiligo Trial Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040960?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:01","pubTimestamp":1788130860,"startTime":"0","endTime":"0","summary":"2300 GMT - The spotlight for Clinuvel Pharmaceuticals is increasingly turning to the readout of the CUV105 trial, says Jefferies. It is due by the end of December. Clinuvel is currently involved in a Phase 3 clinical trial of afamelanotide as a potential treatment for vitiligo, which affects some 0.75% of the U.S. population. Current treatment options are suboptimal, analyst David Stanton says. Vitiligo is a repigmentation disease with a large total addressable market of up to US$570 million in the first two years of entry to the market. \"Given Phase 2 trial results, we believe afamelanotide may eventually offer a more definitive, full-body solution than current standards of care in vitiligo,\" says Jefferies, which has a buy call on Clinuvel.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663470080","title":"Monash IVF Group - Appoints Catherine West as Chair-Elect to Succeed Richard Davis as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2663470080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663470080?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:30","pubTimestamp":1788129048,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUE3YWG98:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","MVF.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070047","title":"Monash IVF Group Ltd-Mvf Board Succession and Renewal","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:30","pubTimestamp":1788129048,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUE3YWG98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVF.AU","BK7113","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004700","title":"Monash IVF Group - Richard Henshaw to Retire on 28 October 2026; Neil Broekhuizen to Retire on 31 August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004700","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004700?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:30","pubTimestamp":1788129048,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUE3YWG98:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","MVF.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663472070","title":"Monash IVF Group Ltd - Expects Financial Performance to Strengthen Through Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2663472070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663472070?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:16","pubTimestamp":1788128209,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nPLX2CG9XX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MVF.AU","BK7113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663104720","title":"Monash IVF Group FY Revenue AUD 269.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663104720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663104720?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:16","pubTimestamp":1788128209,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nPLX2CG9XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MVF.AU","BK7113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663475360","title":"ASX Growth Companies With High Insider Ownership In August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663475360","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663475360?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:08","pubTimestamp":1788116882,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with concerns over potential interest rate increases and recent fluctuations in capital expenditure, investors are closely monitoring growth companies with high insider ownership on the ASX. In such an environment, stocks that combine robust growth potential with significant insider stakes can offer a unique perspective on confidence in their long-term prospects.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-sks/sks-technologies-group-shares/news/asx-growth-companies-with-high-insider-ownership-in-august-2-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-sks/sks-technologies-group-shares/news/asx-growth-companies-with-high-insider-ownership-in-august-2-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XKO.AU","AWJ.AU","BK7017","BK7095","OZR.AU","XAO.AU","BK7036","IOZ.AU","AR1.AU","ZYAU.AU","BBOZ.AU","IISV.AU","GEAR.AU","BK7096","BK7016","DACE.AU","XJO.AU","BK7093","PDI.AU","KOA.AU","SKS.AU","TTT.AU","BK7104","VAP.AU","AEM.AU","FRS.AU","BK7501","VAS.AU","QRE.AU","IIGF.AU","BK7084","ELS.AU","AV1.AU","EIGA.AU","BK7110","BK7508","BK7023","SLF.AU","E200.AU","OZF.AU","SPL.AU","WZR.AU","BK7107","BEAR.AU","STW.AU","QFN.AU","GIVE.AU","IMLC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663506047","title":"ASX August 2026 Stocks Estimated Below Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2663506047","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663506047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:04","pubTimestamp":1788116668,"startTime":"0","endTime":"0","summary":"The Australian market has been experiencing a cautious phase, with the S&P/ASX 200 closing lower amid concerns over potential interest rate hikes and mixed earnings reports. Despite these challenges, the search for undervalued stocks remains crucial as investors look to capitalize on opportunities that may be trading below their intrinsic value in a fluctuating economic environment.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7121000-choice1-main-header/1585186619635","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7121000-choice1-main-header/1585186619635"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-zip/zip-co-shares/news/asx-august-2026-stocks-estimated-below-fair-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-zip/zip-co-shares/news/asx-august-2026-stocks-estimated-below-fair-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7126","BGL.AU","BK7016","BK7084","SDR.AU","BK7104","LOV.AU","BK7051","BK7093","SDV.AU","FCL.AU","ZIP.AU","BK7095","BK7017","BK7015","PNV.AU","SLC.AU","ABV.AU","CAT.AU","NIC.AU","NXL.AU","BK7128","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800678","title":"CSL’s latest result suggests the worst may be over","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800678","media":"Morning Star AU","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800678?lang=en_us&edition=fundamental","pubTime":"2026-08-31 00:00","pubTimestamp":1788105600,"startTime":"0","endTime":"0","summary":"CSL’s (ASX:CSL) earnings result was not particularly impressive on the surface. Underlying earnings fell 2%, while a USD 7.1 billion impairment charge pushed statutory earnings into the red. Despite t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/csls-latest-result-suggests-worst-may-be-over","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/csls-latest-result-suggests-worst-may-be-over","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["FEBU","GXDW","VOTE","BK7067","JOYT","PMDE","CSL.AU","CDIG","BK7511","RGLO","BK7508","DECU","BK7501","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663445130","title":"NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2663445130","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663445130?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:22","pubTimestamp":1788088921,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) is back on investor radars after recent share price moves and a fresh look at its valuation profile. The stock closed at US$914.69, with an estimated intrinsic discount of 32.5%.\nOver the past few months NewMarket’s share price has gained momentum, with a 30 day share price return of 7.6% and a 90 day share price return of 14.7%. The 5 year total shareholder return of 193.4% highlights how strongly long term holders have been rewarded.\nSpot similar momentum stories by scanning...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JOYT","NEU.AU","PMDE","VGFPF","BK7096","BK7508","BK4109","DECU","DCF","GXDW","FEBU","NEU","VOTE","RGLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663721010","title":"3 Founder Led Australian Stocks Built For Higher Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2663721010","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663721010?lang=en_us&edition=fundamental","pubTime":"2026-08-30 01:17","pubTimestamp":1788023852,"startTime":"0","endTime":"0","summary":"Central banks are hinting that interest rates could stay higher for longer as inflation pressures persist. That kind of backdrop tends to reward leaders who think and act like long term owners. Founder led companies often fit that profile, with executives whose own wealth is tied to what you care about: long term equity value. This article highlights 3 founder led stocks from our screener that show how that mindset looks in practice.\nThe three founder led stocks in this article are just a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/3-founder-led-australian-stocks-built-for-higher-rates","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/3-founder-led-australian-stocks-built-for-higher-rates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7043","DACE.AU","MSB.AU","IIGF.AU","BK7501","IOZ.AU","BK7067","OZR.AU","BK7094","PME.AU","IMLC.AU","BK7511","EIGA.AU","GEAR.AU","SLF.AU","IISV.AU","QFN.AU","VAS.AU","MQG.AU","ZYAU.AU","E200.AU","BK7042","STW.AU","XKO.AU","BEAR.AU","BBOZ.AU","OZF.AU","VAP.AU","XAO.AU","BK7046","BK7508","XJO.AU","QRE.AU","MAQ.AU","GIVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019945","title":"Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019945","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019945?lang=en_us&edition=fundamental","pubTime":"2026-08-29 06:23","pubTimestamp":1787955839,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers.\nFor long term holders, the key point is that this remains a highly...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663192110","title":"3 Penny Stocks With Real Revenue And Solid Balance Sheets","url":"https://stock-news.laohu8.com/highlight/detail?id=2663192110","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663192110?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:29","pubTimestamp":1787952565,"startTime":"0","endTime":"0","summary":"Global inflation readings in Europe are keeping interest rate expectations elevated, which keeps borrowing costs in focus for smaller companies. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for low priced stocks that still show solid financial health, so investors are not just chasing cheap tickers. This article highlights three stocks from the screener that may be worth considering for your watchlist.\nThe three stocks highlighted below are just a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-real-revenue-and-solid-balance-sheets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-real-revenue-and-solid-balance-sheets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7506","XBI","BK4588","ALK.AU","LABU","BK7067","SIG.AU","BK4581","BK4585","XLV","BK7104","BK7508","BK7103","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663601992","title":"Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2663601992","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663601992?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:17","pubTimestamp":1787951858,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-have-made-a-financial-statement-on-botanix-pharmace","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-have-made-a-financial-statement-on-botanix-pharmace","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7508","BK7502","BOT.AU","BOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701921","title":"Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701921","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701921?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:28","pubTimestamp":1787948898,"startTime":"0","endTime":"0","summary":"Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway.\nConcerned by Actinogen Medical's cash runway...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064690","title":"Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064690","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662064690?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:43","pubTimestamp":1787913835,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of overweight and mean price target of AU$19.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":112,"code":"91000000","status":"200"}]}}